ZBIO

Zenas BioPharma, Inc.

Zenas BioPharma, Inc. (ZBIO) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Value (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C-
Factor Score 1.9 / 5.0
Growth
B+
Factor Score 3.5 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.8
EV / EBITDA -5.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -8.2%
Price Return 12M -21.8%
Catalyst Signal 0.00
Market Cap $1.9B
TTM Revenue $11.0M
Price / Sales 172.7
ROE -265.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C- (1.9) B+ (3.5) C (2.2) B (3.2) C+ (2.6) C+ (2.7)
2026-11-08 F (0.0) B+ (3.7) C- (1.9) B- (3.1) C+ (2.6) C (2.3)
2026-11-01 F (0.0) B+ (3.6) C- (1.9) B (3.2) C+ (2.7) C (2.3)
2026-10-25 F (0.0) B+ (3.6) C- (1.9) B- (3.0) C+ (2.6) C (2.2)
2026-10-18 F (0.0) B+ (3.6) C- (1.9) B- (3.0) C+ (2.6) C (2.2)
Page 1 of 4